Khan, Assistant Professor in BME and Immunology and Canada Research Chair in Nucleic Acid Therapeutics at the University of Toronto, on: - Why lncRNA is far from "junk" - and what it could mean for future therapeutics - The role of LNP delivery systems in unlocking clinical potential - Why creativity in LNP design is essential Read the full interview #NucleicAcids #lncRNA #LipidNanoparticles #GeneMedicine #Therapeutics #NucleicAcidInsights #NAI #lnp #RNA To view or add a comment, sign in : - A fascinating new interview explores the emerging field of dark transcriptome medicines and the therapeutic potential of long noncoding RNA
For individuals who are unable to achieve glycemic control with a lower dose, it may be necessary to switch to a higher dose
As is shown by a recent report, liraglutide plus metformin improves cell function during the treatment period, but the effects disappears after the treatment is stopped, in adults with impaired glucose tolerance or newly-diagnosed T2D[39]
Area, Barhi-131101 Marketer details Name: Converge Biotech Address: 7-2-1813,/5/A/1, Vasavi's Central Court, Unit-II , 3rd Floor, Czech Colony, Sanath Nagar, Hyderabad - 500018., Telangana state, India